Controlled trial of D-penicillamine with low dosis in the treatment of chronic liver diseases.

Controlled trial of D-penicillamine was carried out with low dosis in 10 patients with chronic persistent hepatitis, 11 patients with chronic aggressive hepatitis and 7 patients with liver cirrhosis. After 6 weeks and 6 months treatment mean values of transaminases improved in patients with chronic persistent hepatitis. The mean serum transaminases levels of the patients with chronic aggressive hepatitis were statistically decreased after 6 weeks treatment but not significantly lower after 6 months treatment than on entry. D-penicillamine is not effective for the treatment of patients with liver cirrhosis. Eight of 36 patients treated were withdrawn from the trial because of adverse drug toxicity side effects.

RCT Entities:   Population Interventions Outcomes